Century Therapeutics (NASDAQ:IPSC – Get Free Report) and Cellectis (NASDAQ:CLLS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.
Risk and Volatility
Century Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500.
Profitability
This table compares Century Therapeutics and Cellectis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Century Therapeutics | -4,837.73% | -61.66% | -31.78% |
| Cellectis | -234.39% | -74.55% | -22.65% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Century Therapeutics | $6.59 million | 6.27 | -$136.67 million | ($1.63) | -0.29 |
| Cellectis | $41.51 million | 1.93 | -$101.06 million | ($0.83) | -1.73 |
Cellectis has higher revenue and earnings than Century Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Century Therapeutics and Cellectis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Century Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
Century Therapeutics presently has a consensus target price of $4.40, suggesting a potential upside of 816.67%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 386.11%. Given Century Therapeutics’ higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Cellectis.
Institutional and Insider Ownership
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 6.8% of Century Therapeutics shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cellectis beats Century Therapeutics on 8 of the 13 factors compared between the two stocks.
About Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
